MA31765B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA31765B1
MA31765B1 MA32755A MA32755A MA31765B1 MA 31765 B1 MA31765 B1 MA 31765B1 MA 32755 A MA32755 A MA 32755A MA 32755 A MA32755 A MA 32755A MA 31765 B1 MA31765 B1 MA 31765B1
Authority
MA
Morocco
Prior art keywords
phenyl
treatment
syndrome
organic compounds
ovaries
Prior art date
Application number
MA32755A
Other languages
Arabic (ar)
English (en)
Inventor
Patrick Chene
Carlos Garcia-Echeverria
Michael Rugaard Jensen
Cornelia Quadt
Thomas Radimerski
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31765B1 publication Critical patent/MA31765B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention porte sur l'utilisation de l'éthylamide de l'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique ou d'un tautomère de celui-ci ou d'un sel pharmaceutiquement acceptable ou d'un hydrate ou d'un solvate pour le traitement du cancer de la vessie, du côlon, du foie, du poumon, du sein, du vagin, des ovaires, du pancréas, du rein, de l'estomac, du tractus gastro-intestinal, de la prostate, de la tête et du cou, de la cavité péritonéale, de la thyroïde, des os, du cerveau, du système nerveux central et/ou du sang et/ou pour le traitement du syndrome myélodyspiastique, de la mastocytose systémique, du syndrome de von hippel-lindau, de la maladie de castleman multicentrique et/ou du psoriasis.
MA32755A 2007-10-12 2010-04-08 Composes organiques MA31765B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118421 2007-10-12
PCT/EP2008/063605 WO2009047323A2 (fr) 2007-10-12 2008-10-10 Composés organiques

Publications (1)

Publication Number Publication Date
MA31765B1 true MA31765B1 (fr) 2010-10-01

Family

ID=38952098

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32755A MA31765B1 (fr) 2007-10-12 2010-04-08 Composes organiques

Country Status (19)

Country Link
US (6) US20100210650A1 (fr)
EP (3) EP3427797A1 (fr)
JP (2) JP5800504B2 (fr)
KR (4) KR101841872B1 (fr)
CN (2) CN104306377A (fr)
AU (1) AU2008309562B2 (fr)
BR (1) BRPI0818559A2 (fr)
CA (1) CA2700795C (fr)
CL (1) CL2008003005A1 (fr)
ES (1) ES2500920T3 (fr)
MA (1) MA31765B1 (fr)
MX (1) MX2010003988A (fr)
PL (1) PL2263751T3 (fr)
PT (1) PT2263751E (fr)
RU (1) RU2491938C2 (fr)
TN (1) TN2010000139A1 (fr)
TW (1) TW200922595A (fr)
WO (1) WO2009047323A2 (fr)
ZA (1) ZA201001546B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140078656A (ko) * 2011-10-14 2014-06-25 노파르티스 아게 증식성 질환의 치료를 위한 hsp90 억제제와 조합된 2-카르복스아미드 시클로아미노 우레아 유도체
CA2902699A1 (fr) * 2013-03-15 2014-09-18 Novartis Ag Marqueur biologique
CA2992629C (fr) * 2015-08-24 2020-06-30 Shanxi Yabao Health Products Co., Ltd. Utilisation de dihydroxyacetone dans la preparation d'un medicament anti-tumoral
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003282512A1 (en) * 2002-10-22 2004-05-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methods of reducing the activity of and reducing the concentration of a mutant kit protein
PT1611112E (pt) * 2003-02-11 2012-11-02 Cancer Rec Tech Ltd Compostos de isoxazole como inibidores de proteínas de choque térmico
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
JP2008536867A (ja) * 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 増殖疾患を処置する際に有用なｈｓｐ９０インヒビターとしての２−アミノ−キナゾリン−５−オン
US20070105862A1 (en) * 2005-11-10 2007-05-10 Milan Bruncko Heat-shock protein binders
KR20090122218A (ko) * 2007-03-01 2009-11-26 노파르티스 아게 ５-(２,４-디히드록시-５-이소프로필-페닐)-４-(４-모르폴린-４-일메틸-페닐)-이속사졸-３-카르복실산 에틸아미드의 산 부가염, 수화물 및 다형체, 및 이들 형태를 포함하는 제제

Also Published As

Publication number Publication date
PL2263751T3 (pl) 2014-12-31
JP2014156475A (ja) 2014-08-28
RU2010118458A (ru) 2011-11-20
AU2008309562A1 (en) 2009-04-16
KR20160143877A (ko) 2016-12-14
WO2009047323A3 (fr) 2009-11-12
RU2491938C2 (ru) 2013-09-10
EP2263751B1 (fr) 2014-07-09
KR20170124642A (ko) 2017-11-10
PT2263751E (pt) 2014-09-10
MX2010003988A (es) 2010-04-27
US20100210650A1 (en) 2010-08-19
WO2009047323A2 (fr) 2009-04-16
JP2011500535A (ja) 2011-01-06
ZA201001546B (en) 2010-10-27
US20160045513A1 (en) 2016-02-18
EP2209529A2 (fr) 2010-07-28
US20140288075A1 (en) 2014-09-25
EP3427797A1 (fr) 2019-01-16
US20120083496A1 (en) 2012-04-05
KR20160040738A (ko) 2016-04-14
TW200922595A (en) 2009-06-01
KR20100075902A (ko) 2010-07-05
JP5800504B2 (ja) 2015-10-28
US20120214813A1 (en) 2012-08-23
TN2010000139A1 (en) 2011-09-26
EP2209529B1 (fr) 2018-09-19
US20160220576A1 (en) 2016-08-04
CN104306377A (zh) 2015-01-28
CL2008003005A1 (es) 2009-05-08
ES2500920T3 (es) 2014-10-01
BRPI0818559A2 (pt) 2015-04-22
KR101841872B1 (ko) 2018-03-26
CA2700795C (fr) 2017-03-07
CN101795728A (zh) 2010-08-04
EP2263751A1 (fr) 2010-12-22
AU2008309562B2 (en) 2012-01-19
CA2700795A1 (fr) 2009-04-16

Similar Documents

Publication Publication Date Title
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA31765B1 (fr) Composes organiques
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA30433B1 (fr) Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
MA30704B1 (fr) Compositions therapeutiques
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
MX2021014287A (es) Nuevos antagonistas ciclicos del receptor b2 de bradiquinina.
JP2009541472A5 (fr)
JP2008542390A5 (fr)
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
EA201992685A1 (ru) Раствор леводопы для инфузий
AU2015365954A1 (en) Use of sigma receptor ligands in osteoarthritis
RU2015117550A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с мек ингибитором
RU2017124612A (ru) Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр
JP2019501134A5 (fr)
BRPI0514765A (pt) compostos orgánicos
ES2961678T3 (es) 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para su uso en la prevención y/o el tratamiento del estrés
BR112022005999A2 (pt) Métodos de tratamento de condições relacionadas ao receptor s1p1
RU2016132400A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с гефитинибом